Analysts advised investors to subscribe to the issue on the company’s competitive strengths which include a product portfolio focused on various customer segments, a distribution network, experienced management, and a dedicated employee base.
Tata Capital has filed preliminary papers for a Rs 15,000 crore plus IPO with Sebi, aiming to list shares by September 2025. The IPO will
Indian pharmaceutical stocks took a hit as Trump’s threat of imposing tariffs on pharma imports spooked investors. Despite India’s strong presence in the US generics
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003